Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT (2016 - 2025)

Historic EBT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.7 million.

  • Enanta Pharmaceuticals' EBT rose 3603.78% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year increase of 2906.83%. This contributed to the annual value of -$83.5 million for FY2025, which is 2906.83% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' EBT is -$18.7 million, which was up 3603.78% from -$18.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year EBT high stood at -$18.2 million for Q2 2025, and its period low was -$37.6 million during Q1 2023.
  • In the last 5 years, Enanta Pharmaceuticals' EBT had a median value of -$29.5 million in 2023 and averaged -$29.0 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 19375.31% in 2021, then soared by 3603.78% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' EBT stood at -$30.2 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 17.26% to -$34.0 million in 2023, then soared by 33.27% to -$22.7 million in 2024, then rose by 17.78% to -$18.7 million in 2025.
  • Its EBT was -$18.7 million in Q3 2025, compared to -$18.2 million in Q2 2025 and -$23.9 million in Q1 2025.